MDMA RESEARCH AT HARBOR-UCLA
An MDMA phase I safety study conducted by Dr. Charles Grob was approved by the FDA in 1992 and completed in 1995. Subsequent efforts to obtain approval for a cancer patient study were rejected twice by the FDA. After formal protests to senior FDA management during the summer of 1999, the FDA agreed to approve an MDMA study in cancer patients.
Read more about this study and the history of MDMA research
Additional links and updates on this site:
Psychobiologic Effects of MDMA in Humans
Investigators: Charles S. Grob, MD, and Russell E. Poland, Ph.D.
Harbor-UCLA Medical Center - Torrance, California, USA
Sponsor: MAPS, Harbor/UCLA
E-mail: Charles Grob; email@example.com, Russell Poland; firstname.lastname@example.org
FDA-approved Phase 1 dose-response safety study .25 to 2.25 mg/kg, dose administration
data for .25 to .75 mg/kg published. Data for 1.00 to 2.25 mg/kg being analysed for
Chang, L, Ernst, T, Grob, CS and Poland, RE (1999) Cerebral 1H MRS Alterations in
Recreational 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Users. Journal of
Magnetic Resonance Imaging 10:521-526.
Grob, C.S. and Poland, R.E. (1997) MDMA. In: Substance Abuse: A Comprehensive
Textbook, Third Edition, Lowinson, J.H, Ruiz, P, Millman, R.B, Langrod, J.G. (Eds),
Williams & Wilkins, Baltimore, pp. 269-275.
Grob CS, Poland RE, Chang L, and Ernst T (1996) Psychobiologic effects of 3,4-
methylenedioxymethamphetamine (MDMA) in humans: methodological considerations and
preliminary observations, Behav Brain Res, 73:103-107.